Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00180765
Status:
WITHDRAWN
Last Update Posted:
2019-07-10
First Post:
2005-09-13
Brief Title:
Regulation of the Release of Inflammatory Mediators From Blood Leukocytes
Sponsor:
Imperial College London
Organization:
Imperial College London
Study Overview
Official Title:
Regulation of the Release of Inflammatory Mediators From Blood Leukocytes A Comparison of Healthy Subjects Healthy Smokers and Patients With COPD
Status:
WITHDRAWN
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
No funding for the study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chronic obstructive pulmonary disease COPD for short involves inflammation inside the air passages of the lungs This inflammation might be partly responsible for the shortness of breath cough and susceptibility to chest infections that form part of COPD Inflammation is caused in part by white blood cells that are attracted from the blood into the air passages Once inside the air passages the white blood cells may change or differentiate and release substances that produce inflammation and attract more white cells The hypothesis is that the lifespan of these cells may also be prolonged such that they produce more inflammatory mediators and in turn perpetuate inflammation The cycle of inflammation may damage the lungs so we want to see what mediators are released by white blood cells and determine if we can inhibit this effect with existing and new drugs We would also like to see the effect of these drugs on the life-span and function of white blood cells We will compare the behaviour and characteristics of white cells with those from healthy smokers and healthy non-smokers to find out if there is anything different about cells from COPD patients
Detailed Description:
The aim of this study is to investigate the mechanisms that regulate the survival of blood leukocytes as well as the synthesis and release of inflammatory mediators from cells from normal individuals and subjects with COPD The hypothesis is that in COPD the life-span of leukocytes such as the neutrophil is enhanced and this may contribute to inflammation a prominent characteristic of this disease by secreting and releasing inflammatory mediators We also suggest that differences may exist in the sensitivity of the various leukocytes to different therapies
Leukocytes will be purified from the peripheral venous blood of patients with COPD as well as healthy individuals We will then investigate the effects of novel and existing therapeutic agents on leukocyte survival and inflammatory mediator synthesis and release We will also examine the regulation and release of enzymes known to damage lung tissue Further studies will be carried out to elucidate the signal transduction pathways that lead to the activation altered longevity and function of leukocytes In other experiments ribonucleic acids or RNA may be extracted form leukocytes to investigate which genes are involved The primary objective is to identify the mechanisms that enhance leukocyte longevity and inflammatory mediator andor enzyme synthesis and release with a view to identifying novel targets for drug therapy
Leukocytes will be purified from the peripheral venous blood of patients with COPD as well as healthy individuals We will then investigate the effects of novel and existing therapeutic agents on leukocyte survival and inflammatory mediator synthesis and release We will also examine the regulation and release of enzymes known to damage lung tissue Further studies will be carried out to elucidate the signal transduction pathways that lead to the activation altered longevity and function of leukocytes In other experiments ribonucleic acids or RNA may be extracted form leukocytes to investigate which genes are involved The primary objective is to identify the mechanisms that enhance leukocyte longevity and inflammatory mediator andor enzyme synthesis and release with a view to identifying novel targets for drug therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None